Presented by: Dennis Leung, Ph.D., Merck & Co. Inc.
Presented Live: November 5, 2015
Nanotechnology has emerged as a powerful new platform for the pharmaceutical industry to help develop new drug therapies and has had a significant impact on drug development from preclinical toxicology studies to commercial marketed products. For example, in the Discovery space, increasing exposure multiples in preclinical species has been a formulation challenge in addressing potential safety issues of drug candidates and nanosuspensions are a potential enabling formulation technology to achieve this while providing line of sight into development and clinical manufacture.
Drug nanoparticles have unique properties that can provide advantages for drug delivery. Due to their small size, nanoparticles increase the bioavailability of poorly water-soluble drugs through increased dissolution rate due to their large surface area. By optimizing the formulation, stable drug nanoparticles with high drug loadings can be achieved. In addition, nanoparticles can be successfully dosed through a wide range of administration routes, ranging from oral, intraperitoneal, intravenous, inhalation, and topical delivery. An overview of current nanotechnology approaches, optimization of formulation parameters, high throughput analytical capabilities, and case studies will be presented.